Key facts
- This page summarizes Stuart Essig's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 May 2023, 17:31.
Stuart Essig - 11 May 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)
- Reporting relationship
- Director
- Issuer ticker
- IDXX
- Reported as of
- 11 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 May 2023, 17:31:46 UTC
- Prior SEC filing
- 07 Apr 2023
- Next SEC filing
- 16 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lily J. Lu, Attorney-in-Fact for Stuart Essig
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stuart Essig filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 15 May 2023.
Change
- Previous filing in this sequence was filed on 07 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IDXX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +344
- Change %
- +25%
- Price
- $0.000000
- Shares after
- 1,717
- Date
- 11 May 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IDXX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -344
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 344
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.
Footnote F2
Not applicable.